Popular search terms:
Search Results
33 results found-
Our scientists are recognized for their contributions to developing breakthrough medicines that have the potential to help patients worldwide.
https://www.cslbehring.com.au/research-and-development/research-and-development-capabilities -
the prophylaxis and treatment of non-surgical and surgical bleeding associated with FVIII deficiency due to haemophilia A.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/biostate-nz-ds2000.pdf -
CSL Behring provides protein-based therapies for bleeding disorders, critical care, pulmonary disease, and other rare illnesses.
https://www.cslbehring.com.au/products -
CSL Behring is a global biotech company leading the way to deliver innovative therapies for rare and serious diseases.
https://www.cslbehring.com.au/our-company -
Isolated deficiency of factor II or factor X is very rare but in severe form they cause a bleeding tendency similar to that seen in classical haemophilia.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/prothrombinexvf-nz-ds-2100.pdf -
the prophylaxis and treatment of non-surgical and surgical bleeding associated with FVIII deficiency due to haemophilia A.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/biostate-au-pi-v3000.pdf -
with haemophilia A, a bleeding your treatment.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/biostate-au-cmi-v2600.pdf -
Gene Therapy (AAV5-Padua FIX) for Treatment of Haemophilia B Haematology •
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2021_.pdf